CRISPR-Based Diagnostics Market Size to Reach USD 12.09 Billion by 2033 as Rapid Molecular Testing, Reagent Demand, and Point-of-Care Innovation Expand Commercial Potential

April 19, 2026 - The global CRISPR-Based Diagnostics Market reached USD 3.04 billion in 2024 and is expected to reach USD 12.09 billion by 2033, growing at a CAGR of 16.7% during 2025-2033, based on the market data provided. The market is expanding as CRISPR moves from a research-driven genome editing tool toward a practical diagnostics platform for infectious disease detection, molecular testing, and faster point-of-care workflows. A closely aligned Grand View Research market summary independently estimated the market at USD 3.084 billion in 2024, which closely supports the scale of the dataset you supplied.

Request Updated Sample Report: https://www.datamintelligence.com/download-sample/crispr-based-diagnostics-market?kailas

Growth is being supported by rising demand across technique, product, application, and end-user segments, especially where CRISPR can deliver high sensitivity, adaptable assay design, and faster molecular detection. Recent company activity suggests the market is still early in commercialization, but platform readiness, assay-development infrastructure, and reagent availability are improving. At the same time, adjacent public market data for CRISPR-based point-of-care diagnostics shows that assay kits and reagents held 61.93% share in 2024, reinforcing how much value is concentrated in consumables and workflow-ready testing products.

Recent Developments

Recent market activity shows that commercialization is being shaped by platform development, translational CRISPR infrastructure, and broader diagnostic readiness. Mammoth Biosciences continues to position its DETECTR® platform as a CRISPR-based molecular diagnostics system adaptable to different molecular targets, multiplexing formats, and existing lab workflows, underscoring the platform flexibility that remains central to market adoption.

On July 16, 2025, Integrated DNA Technologies (IDT) announced an expansion of its translational CRISPR portfolio, including product innovation updates, off-target analysis services, and other solutions designed to bridge discovery research and clinical translation. While this update is broader than diagnostics alone, it is highly relevant because CRISPR-based diagnostics depends heavily on assay-enabling reagents, guide design, and translational workflow support.

On the regulatory side, the FDA continues to maintain active frameworks for molecular diagnostics, including emergency-use and in vitro diagnostic pathways that have previously supported rapid deployment of novel nucleic-acid testing formats. That environment remains important for CRISPR diagnostics because commercialization is closely tied to evolving molecular test regulation and clinical validation standards.

Japan is also strengthening the broader genomic medicine environment. The Ministry of Health, Labour and Welfare states that the Genome Medicine Promotion Act was promulgated and enforced in June 2023, and that a basic plan for genome medicine policy was established in November 2025. That creates a more supportive long-term policy backdrop for genomic and molecular diagnostics, including CRISPR-based approaches.

Segment Analysis
By Product: Kits and Reagents

Kits and reagents appear to be the largest product segment in the market because CRISPR diagnostics relies heavily on consumables, assay chemistry, guide components, enzymes, and ready-to-use testing systems. In the adjacent CRISPR-based point-of-care diagnostics market, assay kits and reagents accounted for 61.93% share in 2024. Applying that share directionally to your 2024 market value of USD 3.04 billion implies an estimated kits and reagents segment size of about USD 1.88 billion. I would treat that value as a directional estimate rather than an exact matched segment total, because the share comes from a closely related CRISPR diagnostics category rather than your exact market table.

By Technique: Cas12-Based Diagnostics

Cas12-based diagnostics is one of the most commercially attractive technique segments because it has become central to CRISPR detection platforms for nucleic acid testing, especially in rapid and point-of-care use cases. Public market data for the adjacent CRISPR-based point-of-care diagnostics market shows Cas12-based technology held 47.03% share in 2024. Applying that share directionally to your 2024 global market size of USD 3.04 billion suggests an estimated Cas12-based opportunity of about USD 1.43 billion. This is a directional benchmark, but it clearly signals that Cas12 platforms are among the leading commercial technique categories in CRISPR diagnostics today.

Market Segmentation

The CRISPR-Based Diagnostics Market is segmented by Technique, Product, Application, End User, and Region. Regionally, the market spans North America, Latin America, Europe, and Asia Pacific. Key companies cited for the market include OraSure Technologies, Inc., Mammoth Biosciences, Inc., Integrated DNA Technologies, and GenScript, among others.

Regional Analysis
United States

The United States remains the most commercially important national market for CRISPR-based diagnostics because of its concentration of molecular diagnostics companies, funding depth, regulatory infrastructure, and clinical adoption capacity. Public open-source sizing for the exact U.S. CRISPR-diagnostics submarket is limited, but Grand View Research reports that North America dominated the CRISPR-based point-of-care diagnostics market with 47.91% share in 2024, and that the U.S. led the regional market. That strongly indicates the U.S. is the largest country opportunity within the current commercialization landscape.

Growth trends in the U.S. are being driven by demand for rapid molecular testing, infectious-disease diagnostics, decentralized care, and continued investment in CRISPR platform development. Policy matters as well. FDA guidance and authorization structures for molecular diagnostics remain central to commercialization, and the U.S. continues to offer the most mature pathway for clinical validation and scaling of novel nucleic-acid test formats. While I do not have a clean country-level revenue figure from an open primary source for this exact niche, the U.S. clearly represents the leading national market on a directional basis.

Japan

Japan is emerging as a meaningful Asia-Pacific opportunity for CRISPR-based diagnostics because of its strong molecular testing base, supportive genomic medicine policy, and continued investment in diagnostic infrastructure. Public apples-to-apples sizing for the exact Japan CRISPR-based diagnostics market is limited, so the best directional anchors come from adjacent diagnostics categories. For example, Japan's diagnostic testing market reached USD 12.6 billion in 2025, while the point-of-care molecular diagnostics market is also projected to expand steadily. These broader categories indicate that Japan offers a sizable addressable environment for advanced molecular diagnostic technologies, including CRISPR-based testing.

Japan's growth trend is closely tied to policy. The Ministry of Health, Labour and Welfare states that the Genome Medicine Promotion Act has been in force since June 2023, and that the government established a basic genome medicine policy plan in November 2025. That policy direction supports a stronger long-term foundation for genomic and molecular diagnostics, especially where emerging techniques need clinical-system legitimacy and coordinated implementation.

Purchase Exclusive Report: https://www.datamintelligence.com/buy-now-page?report=crispr-based-diagnostics-market?kailas

Company Profiles
OraSure Technologies, Inc.

OraSure is relevant in this market because it operates at the intersection of infectious disease diagnostics, decentralized testing, and sample-collection technologies. OraSure's official site says the company focuses on decentralizing diagnostics and enabling access to healthcare through non-invasive testing devices and sample-management solutions. That positioning is important in CRISPR diagnostics because market growth is increasingly tied to faster, simpler, and more accessible molecular testing formats rather than centralized lab-only workflows.

Mammoth Biosciences, Inc.

Mammoth Biosciences is one of the most visible CRISPR-native companies in the diagnostics space. Its official diagnostics page positions DETECTR® as a CRISPR-based detection platform that can search for specific nucleic-acid targets and provide actionable clinical information across multiple testing formats. That gives Mammoth one of the clearest pure-play platform stories in the market, especially in areas where flexibility, multiplexing, and rapid adaptation matter.

Integrated DNA Technologies

IDT is especially important because CRISPR diagnostics depends heavily on oligos, guide RNAs, Cas-related workflow components, and translational support tools. IDT's July 2025 announcement on its expanded translational CRISPR portfolio highlighted new purity offerings, off-target analysis services, and additional solutions to support CRISPR development. As part of Danaher, IDT also benefits from broader life sciences scale and manufacturing depth, which supports its relevance in the supply chain underpinning CRISPR diagnostics.

Analyst View

The CRISPR-Based Diagnostics Market is moving from scientific promise toward a more practical commercialization phase built around kits and reagents, Cas12-based detection approaches, and broader rapid-testing use cases. The United States remains the clearest commercial scale market because of regulatory maturity and company concentration, while Japan looks increasingly attractive because genomic medicine policy is becoming more formalized. Vendors and platform providers that can combine assay reliability, workflow simplicity, and scalable reagent support are likely to capture the greatest share of growth as the market advances toward USD 12.09 billion by 2033.

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.